Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up

Madrigal Pharmaceuticals (MDGL) reported first-quarter 2025 loss of $3.32 per share, narrower than the Zacks Consensus Estimate of a loss of$3.62. In the year-ago quarter, the company had incurred a loss of $7.38 per share.During the quarter, the company generated total revenues of$137.3 million, entirely from product sales of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom), which was approved last year. The metric beat the Zacks Consensus Estimate of $114 million. ...